Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Bendafolin 10 mg/ml Injektionslösung, Benda-5 FU 50 mg/ml Injektionslösung, Xtandi - 40 mg film-coated tablets, Zirabev 25 mg/ml concentrate for solution for infusion, BENDAFOLIN 10 mg/ml Injektionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, 5-Флуороурацил Ебеве 50 mg/ml концентрат за инжекционен и инфузионен разтвор., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung, Zirabev 25 mg/ml concentrate for solution for infusion
GlaxoSmithKline Biologicals S.A.
Neoplasms
1 trial -
Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen.
GlaxoSmithKline Biologicals S.A.
Systemic Lupus Erythematosus
1 trial -
Buffer S9b Solution for suspension for injection
GlaxoSmithKline Biologicals S.A.
Hepatitis B, Chronic
1 trial -
Buffer S9b Solution for suspension for injection
GlaxoSmithKline Biologicals S.A.
Hepatitis B, Chronic
1 trial -
CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé, Capecitabine Accord 150 mg film-coated tablets, Oxaliplatin Bendalis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Capecitabin "Zentiva", filmovertrukne tabletter, Capecitabina Zentiva 500 mg compresse rivestite con film., Capecitabine Zentiva 150 mg filmdragerade tabletter, Capecitabin "Zentiva", filmovertrukne tabletter, CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé,
GlaxoSmithKline Biologicals S.A.
MMRp/ MSS colon cancer
1 trial -
Carboplatino Hikma 10 mg/ml soluzione per infusione, Avastin 25 mg/ml concentrate for solution for infusion., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, JEMPERLI 500 mg concentrate for solution for infusion
GlaxoSmithKline Biologicals S.A.
Tumours, Gynecological
1 trial -
Dectova 10 mg/mL solution for infusion
GlaxoSmithKline Biologicals S.A.
Influenza, Human
1 trial -
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)
GlaxoSmithKline Biologicals S.A.
Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
1 trial -
Isatuximab, Dexa-ratiopharm® 8 mg Injektionslösung, Fortecortin® 2 mg Tabletten, Revlimid 15 mg hard capsules, Zelvina 2.5 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 2.5 mg hard capsules, Zelvina 5 mg hard capsules, Zelvina 25 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Zelvina 10 mg hard capsules, Revlimid 25 mg hard capsules, Imnovid 1 mg hard capsules, Dexamethason 8 mg GALEN® Tabletten, Nirogacestat, Isatuximab, Nirogacestat, Dexa 8 mg inject JENAPHARM Injekti
GlaxoSmithKline Biologicals S.A.
Multiple Myeloma
1 trial -
JEMPERLI 500 mg concentrate for solution for infusion
GlaxoSmithKline Biologicals S.A.
Neoplasms, Head and Neck
1 trial -
JEMPERLI 500 mg concentrate for solution for infusion
GlaxoSmithKline Biologicals S.A.
Neoplasms, Rectal
1 trial -
JEMPERLI 500 mg concentrate for solution for infusion
GlaxoSmithKline Biologicals S.A.
Relapsed/Refractory Tumors
1 trial -
JEMPERLI 500 mg concentrate for solution for infusion
GlaxoSmithKline Biologicals S.A.
Neoplasms, Colorectal
1 trial -
JEMPERLI 500 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
GlaxoSmithKline Biologicals S.A.
Lung Cancer, Non-Small Cell
1 trial -
Locally Sourced 0.9% Sodium Chloride
GlaxoSmithKline Biologicals S.A.
Dermatitis, Atopic
1 trial -
Locally Sourced 0.9% Sodium Chloride
GlaxoSmithKline Biologicals S.A.
Dermatitis, Atopic
1 trial -
NaCl 0.9% solution
GlaxoSmithKline Biologicals S.A.
Meningitis, Meningococcal
1 trial -
NaCl solution
GlaxoSmithKline Biologicals S.A.
Herpes Simplex
1 trial -
Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP
GlaxoSmithKline Biologicals S.A.
Infections, Meningococcal
1 trial -
POMALIDOMIDE, POMALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, BORTEZOMIB, POMALIDOMIDE, CARFILZOMIB, POMALIDOMIDE, CARFILZOMIB, DEXAMETHASONE
GlaxoSmithKline Biologicals S.A.
Relapsed or Refractory Multiple Myeloma
1 trial -
Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin-Teva 10 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion, JEMPERLI 500 mg concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion.
GlaxoSmithKline Biologicals S.A.
Lung Cancer, Non-Small Cell
1 trial -
Placebo for Bepirovirsen Solution for Injection, 150 mg/mL SSD
GlaxoSmithKline Biologicals S.A.
Hepatitis B
1 trial -
Placebo for GSK5784283.
GlaxoSmithKline Biologicals S.A.
Asthma
1 trial -
Placebo to Match GSK3915393 Tablet
GlaxoSmithKline Biologicals S.A.
Idiopathic Pulmonary Fibrosis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources